To the full analysis
Aquestive Therapeutics stock: growth
AQSTAquestive Therapeutics reported $44.55M in revenue for fiscal 2025, down 22.6% on the prior year, down 0.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−1.7%
per year from 2016 to 2025, per share −17.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | −0.6% | −1.7% |
| Revenue per share | −23.1% | −17.7% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $51.79M | −$9.6M | −$9.15M |
| 2017 | $66.92M | −$8.94M | $3.76M |
| 2018 | $67.43M | −$61.38M | −$14.82M |
| 2019 | $52.61M | −$66.25M | −$60.87M |
| 2020 | $45.85M | −$55.78M | −$45.98M |
| 2021 | $50.83M | −$70.54M | −$33.89M |
| 2022 | $47.68M | −$54.41M | −$12.31M |
| 2023 | $50.58M | −$7.87M | −$7.38M |
| 2024 | $57.56M | −$44.14M | −$35.92M |
| 2025 | $44.55M | −$83.78M | −$52.99M |
Revenue by segment
How Aquestive Therapeutics, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Manufacture and Supply Revenue90%
- License and Royalty Revenue8%
- Co-Development and Research Fees3%
Figures as a table
| 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|
| Manufacture and Supply Revenue | $43.81M | $39.98M | $40.23M | 90.3% |
| License and Royalty Revenue | $5.38M | $15.35M | $3.52M | 7.9% |
| Co-Development and Research Fees | $1.4M | $1.93M | $1.28M | 2.9% |
| Total revenue | $50.58M | $57.56M | $44.55M | 100% |
Revenue by region
Where Aquestive Therapeutics, Inc. generates its revenue.
- United States66%
- Outside the US34%
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| United States | $48.29M | $40.96M | $42.86M | $39.92M | $37.1M | $39.93M | $29.6M | 66.5% |
| Outside the US | $4.32M | $4.89M | $7.97M | $7.76M | $13.48M | $17.63M | $14.94M | 33.5% |
| Total revenue | $52.61M | $45.85M | $50.83M | $47.68M | $50.58M | $57.56M | $44.55M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2019)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.